A TLR7-Nanoparticle Adjuvant Promotes a Broad Immune Response against Heterologous Strains of Influenza and SARS-CoV-2

Researchers describe a polymeric Toll-like receptor 7 agonist nanoparticle (TLR7-NP) adjuvant, which enhanced lymph node targeting, and lead to persistent activation of immune cells and broad immune responses. They tested responses to this TLR7-NP using human tonsil organoids, and other methods.